<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185065</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00119702</org_study_id>
    <nct_id>NCT03185065</nct_id>
  </id_info>
  <brief_title>Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis</brief_title>
  <acronym>TRIUMPHANT-MS</acronym>
  <official_title>Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants
      and investigators), multicenter trial of 3 commonly used medications for treatment of
      MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued
      subjects with MS defined by McDonald Criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind
      (participants and investigators), multicenter trial of 3 commonly used medications for
      treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in
      fatigued subjects with MS defined by McDonald Criteria.

      Using a balanced Latin-square crossover design, subjects will be allocated, in a
      double-blind, randomized fashion, to one of the four treatment sequences (Figure 1): 1)
      amantadine, placebo, modafinil, methylphenidate; 2) placebo, methylphenidate, amantadine,
      modafinil; 3) modafinil, amantadine, methylphenidate, placebo; and 4) methylphenidate,
      modafinil, placebo and amantadine. Each medication will be titrated over four weeks to the
      participants' highest tolerated dose or the pre-defined highest dose. The dosing and
      titration schedule of the study medications are depicted in Figure 2. Each treatment period
      will be 6 weeks and there will be a 2-week washout period between each treatment period. At
      the beginning of the trial, a biostatistician at University of California, San Francisco
      (UCSF) will prepare a concealed allocation schedule, randomly assigning the four sequences,
      in blocks of 4, to a consecutive series of numbers and at the time of enrollment, each
      participant will be assigned the next consecutive number (and hence the sequence of study
      medications).

      The primary endpoint of the study will be fatigue severity as measured by the MFIS score,
      between 26th and 35th day of each treatment period (while the patient is taking the maximal
      tolerated or target dose). The MFIS is a validated patient-reported outcome. The
      questionnaire will be administered remotely (through internet, phone or mailed forms) and the
      participants can answer the questions in few minutes while at home or at their work place.
      The questionnaire has been validated in English and Spanish.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized, placebo‐controlled, crossover, 4‐sequence, 4‐period, double‐blind, multicenter trial of 3 commonly used medications for treatment of Multiple Sclerosis related fatigue versus placebo in fatigued subjects with MS.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>modified fatigue impact scale (MFIS) score</measure>
    <time_frame>Week 5 of each treatment period</time_frame>
    <description>MFIS score at the end o each treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuro-QoL Item Bank - Fatigue score</measure>
    <time_frame>Week 5 of each treatment period</time_frame>
    <description>Neuro-QoL Item Bank - Fatigue score at the end o each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS) score</measure>
    <time_frame>Week 5 of each treatment period</time_frame>
    <description>ESS score at the end o each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?&quot;</measure>
    <time_frame>Week 5 of each treatment period</time_frame>
    <description>Participants will answer to this question yes or no.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Fatigue in Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amantadine, placebo, modafinil, methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo, methylphenidate, amantadine, modafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil, amantadine, methylphenidate, placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylphenidate, modafinil, placebo and amantadine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <description>100 mg of amantadine increased to 200 mg of amantadine, if tolerated</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>100 mg of modafinil increased to 200 mg of modafinil, if tolerated</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>1 placebo capsule increased to max of 2 capsules twice daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age 18 years and older.

          -  Females of childbearing age must have a negative urine pregnancy test at baseline and
             use an effective method of contraception during the study.

          -  Diagnosis of MS (according to the 2010 McDonald criteria).

          -  Expanded Disability Status Scale (EDSS) score at the time of screening 0.0-7.0.

          -  Fatigue reportedly present and screening Modified Fatigue Impact Scale (MFIS) score
             more than 33.

          -  At least a two-week washout for any fatigue-related drug, including study medications.

        Exclusion criteria:

          -  Neurodegenerative disorders other than relapsing or progressive MS.

          -  Breastfeeding or pregnant.

          -  History of coronary artery disease or congestive heart failure.

          -  Uncontrolled hypertension at screening (history of high blood pressure and screening
             systolic blood pressure &gt;160 or diastolic blood pressure&gt;100).

          -  Glomerular Filtration Rate (GFR) (glomerular filtration rate) &lt; 50.

          -  Abnormal liver function at screening (AST or Alanine Aminotransferase (ALT) more than
             twice the upper limit of normal).

          -  Terminal medical conditions.

          -  Currently treated for active malignancy.

          -  Planned surgery or move within 8 months of screening.

          -  Alcohol or substance abuse in the past year (except marijuana or other cannabinoids).

          -  A history of intolerance or allergic or anaphylactic reaction to amantadine,
             modafinil, methylphenidate or any component of the preparation.

          -  Clinically unstable medical or psychiatric disorders that require acute treatment as
             determined by the PI.

          -  Concurrent use of monoamine oxidase inhibitors-B.

          -  Hypersensitivity/idiosyncrasy to sympathomimetic amines

          -  Inability to communicate or answer the questionnaires in English or Spanish.

          -  Severe untreated anemia (blood hemoglobin &lt;9gr/dl)

          -  History of untreated hypothyroidism

          -  History of untreated sleep apnea

          -  History of long QT syndrome, atrial fibrillation or tachyarrhythmias (other than sinus
             tachycardia)

          -  History of ischemic or hemorrhagic stroke

          -  History of glaucoma

          -  History of Tourette syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bardia Nourbakhsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bardia Nourbakhsh, MD</last_name>
    <phone>2677023399</phone>
    <email>bnourba1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nisha Raj Revirajan, MD, CCRC</last_name>
    <phone>4155027220</phone>
    <email>NishaRaj.Revirajan@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nisha Raj Revirajan, MD, CCRC</last_name>
      <phone>415-502-7220</phone>
      <email>NishaRaj.Revirajan@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle Waubant, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Morris, BSN, RN</last_name>
      <phone>443-287-9998</phone>
      <email>bmorri25@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

